



# Antibiotics – Inhaled aztreonam (CAYSTON®)

## WA.PHAR.31 Antibiotics Inhaled Aztreonam (CAYSTON)

**Related medical policies:**

- Antibiotics – Inhaled aminoglycosides

### Medical necessity

Drug	Medical Necessity
aztreonam (CAYSTON®)	Cayston® may be considered medically necessary when: Used to treat patients with cystic fibrosis (CF) known to have <i>Pseudomonas aeruginosa</i> in the lungs

### Clinical policy:

Drug	Clinical Criteria (Initial Approval)
aztreonam (CAYSTON®)	<p>Cayston® may be covered when ALL of the following are met:</p> <ol style="list-style-type: none"> <li>1. Diagnosis of cystic fibrosis (CF)</li> <li>2. Positive culture for <i>Pseudomonas aeruginosa</i> infection in the lungs</li> <li>3. <b>NONE</b> of the following:               <ol style="list-style-type: none"> <li>a. Less than (&lt;) 7 years of age</li> <li>b. FEV<sub>1</sub> less than (&lt;) 25% or greater than (&gt;) 75% predicted</li> <li>c. Positive colonization with <i>Burkholderia cepacia</i></li> </ol> </li> </ol> <p><b>Approve for 12 months</b></p>
	Criteria (Reauthorization)
	<p>Documentation of positive clinical response</p> <p><b>Approve for 12 months</b></p>

### Dosage and quantity limits

Drug Name	Dose and Quantity Limits
Aztreonam (CAYSTON®)	84mL (56 ampules) per 28-days

### References

1. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. [cited 2016 Dec 19]. Available: <https://www.guideline.gov>.
2. Cayston [package insert]. Foster City, CA: Gilead Sciences Inc; 2014.